Breathing new life into the treatment of autoimmune pulmonary alveolar proteinosis (aPAP)

About Savara

Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases.

Learn about Savara

Our Science

Our science is fueled by our desire to provide improved treatment options for people living with rare respiratory diseases.

More about our indication

---

In Development

Our lead product candidate, MOLBREEVI*, is an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

What’s in development

Information for Investors

View our press releases, events, presentations, and other important investor information.

Learn more

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.